Use of rituximab in childhood idiopathic nephrotic syndrome
Rituximab is an established therapy in children with idiopathic nephrotic syndrome to
sustain short-to medium-term disease remission and avoid steroid toxicities. Recent trials …
sustain short-to medium-term disease remission and avoid steroid toxicities. Recent trials …
Current understanding of nephrotic syndrome in children
TK Mattoo, S Sanjad - Pediatric Clinics, 2022 - pediatric.theclinics.com
Nephrotic syndrome (NS) in children is characterized by the presence of significant
proteinuria, hypoalbuminemia, and edema. About 90% of the cases between 1 and 10 years …
proteinuria, hypoalbuminemia, and edema. About 90% of the cases between 1 and 10 years …
Evaluation of daily low-dose prednisolone during upper respiratory tract infection to prevent relapse in children with relapsing steroid-sensitive nephrotic syndrome …
Importance In children with corticosteroid-sensitive nephrotic syndrome, many relapses are
triggered by upper respiratory tract infections. Four small studies found that administration of …
triggered by upper respiratory tract infections. Four small studies found that administration of …
Consensus guidelines on management of steroid resistant nephrotic syndrome
A Vasudevan, R Thergaonkar, M Mantan… - Asian Journal of …, 2021 - journals.lww.com
Objective: To frame revised guidelines on diagnosis and evaluation, treatment and follow-
up, and supportive care of patients with the illness. Process: The guidelines combine …
up, and supportive care of patients with the illness. Process: The guidelines combine …
Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects
Background Sequential rituximab (RTX) administration has emerged as an important
strategy to sustain remission of disease in patients with difficult-to-treat nephrotic syndrome …
strategy to sustain remission of disease in patients with difficult-to-treat nephrotic syndrome …
Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review
FF Lai, EY Chan, K Tullus, AL Ma - Pediatric Nephrology, 2024 - Springer
Immunosuppressants are commonly used as steroid-sparing agents in childhood idiopathic
nephrotic syndrome (NS) to induce and sustain remissions. These drugs have narrow …
nephrotic syndrome (NS) to induce and sustain remissions. These drugs have narrow …
Clinical practice guidelines for nephrotic syndrome: consensus is emerging
Nephrotic syndrome is one of the most common chronic kidney diseases (CKD) in children
with an estimated incidence of 2.92 (range 1.15–16.9) per 100,000 children per year [1]. The …
with an estimated incidence of 2.92 (range 1.15–16.9) per 100,000 children per year [1]. The …
Childhood Nephrotic Syndrome in Africa: Epidemiology, Treatment Trends, and Outcomes
AD Ademola, AO Asinobi, MA Alao, WA Olowu - Seminars in Nephrology, 2022 - Elsevier
Nephrotic syndrome is a common childhood glomerular disease that is associated with
massive proteinuria and edema. Children with nephrotic syndrome are at risk of chronic …
massive proteinuria and edema. Children with nephrotic syndrome are at risk of chronic …
Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis
K Nagai - Medicina, 2023 - mdpi.com
Therapeutic options with immunosuppressive agents for glomerular diseases have widened
with refinements to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines …
with refinements to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines …